MNC Innovative Company of the year 2017 Nominees

November 1, 2017

MNC Innovative Company of the year 2017 Nominees Overview

https://www.facebook.com/Pharmaleader/posts/1747139965310173

The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value, as per a report by Equity Master. India is the largest provider of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume. Of late, consolidation has become an important characteristic of the Indian pharmaceutical market as the industry is highly fragmented. The drugs and pharmaceuticals sector attracted cumulative FDI inflows worth US$ 14.71 billion between April 2000 and March 2017, according to data released by the Department of Industrial Policy and Promotion (DIPP).

MNC Innovative Company of d year nominees #MenariniIndia @galdermaconnect
@galderma @BayerPharma @AbbottNews @MerckIndia @Boehringer pic.twitter.com/gsFkJYpL2O

— Pharmaleaders (@pharmaleader) November 1, 2017

The inflow of foreign direct investments (FDI) to India has dramatically increased since the latter half of the 1990s. There has been a significant elevation in value and number of cross-border acquisitions in India.Hence, mergers & acquisitions (M&A) will continue to sustain as the most favoured route for investing in India through FDI channel in the coming years also. Some factors that will drive M&A in India are reasonable valuation, diversifications, improved sentiments (due to GST & demonetization) and a large growing market.Today, India is called as the ‘pharmacy of the world’, which has been the result of a long and arduous journey. The future of the pharmaceutical industry will be a combination of differentiated products, research, genetics, immunotherapy and pharma tech. However, in order to sustain the robust growth rate and to service their evolving customers better, companies will have to adopt new business models.

MNC Innovative Company of the year 2017

Loading…